vascuCAP vs Huxley SANSA Home Sleep Apnea Test (1000-00)
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 60/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A, vascuCAP, focuses on AI-powered analysis of CT angiography for quantifying plaque composition and assessing cardiovascular risk. In contrast, Tool B, Huxley SANSA, is an AI-driven wearable patch designed for home diagnosis of sleep apnea and cardiac arrhythmias. While both tools fall under the broad category of Cardiology AI, they address distinct diagnostic needs and utilize different data modalities (imaging vs. physiological monitoring).
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
vascuCAP (now ElucidVivo/PlaqueIQ) is an AI software for non-invasive CT angiography analysis, quantifying plaque composition and assessing cardiovascular risk to optimize treatment decisions. Huxley SANSA is an FDA-cleared, AI-powered wearable patch for home sleep apnea and cardiac arrhythmia diagnosis, offering an app-free, cellular-enabled solution for streamlined patient care.
vascuCAP analyzes routinely-available CT angiography images to characterize plaque tissues and provide insights into plaque characteristics. Huxley SANSA collects 9 physiological data channels via a wearable chest patch, which then uploads data wirelessly using built-in cellular capability for analysis.
vascuCAP is designed for Cardiology, Radiology, and Vascular Surgery specialties, aiding in the assessment of cardiovascular disease. Huxley SANSA serves Cardiology, Pulmonology, and Sleep Medicine for diagnosing sleep apnea and cardiac arrhythmias.
vascuCAP quantifies lipid-rich necrotic core, calcification, non-calcified matrix, and intraplaque hemorrhage from CT scans, supporting personalized treatment decisions and risk stratification for stroke and heart attack. Huxley SANSA uses 9 physiological data channels, including ECG, SpO2, and sleep/wake staging, to diagnose home sleep apnea and cardiac arrhythmias.
vascuCAP's plaque quantification and characterization are histologically-validated, using a biobank of tissue specimens as an objective truth standard. Huxley SANSA has been validated against polysomnography (PSG) for its diagnostic capabilities, demonstrating high accuracy, sensitivity, and specificity in sleep apnea detection.